Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

September 07, 2011 08:00 ET

Trimel Pharmaceuticals Corporation to Present at Upcoming Scientific and Investor Conferences

TORONTO, ONTARIO--(Marketwire - Sept. 7, 2011) - Trimel Pharmaceuticals Corporation (TSX:TRL) announced today that it has been invited to present scientific clinical data at the 4th International Symposium on Testosterone being held in Munich, Germany from October 1st to 4th. Trimel will be presenting pioneering clinical data which the company generated in a Clinical study concluded earlier this year. The data to be presented will report on the novel TBS-2 product currently in development designed to treat Female Anorgasmia and associated distress.

Separately Trimel will be presenting a corporate overview of its operations and meeting with investors at the Rodman & Renshaw Annual Healthcare Conference in New York Tuesday September 13, 2011, at 4:30pm Eastern Daylight Time. The presentation materials will also be available on the Trimel website at www.trimelpharmaceuticals.com.

Trimel is currently in mid-stage development stage of a treatment for Anorgasmia. Anorgasmia is an indication recognized by the Food and Drug Administration, or FDA, as a form of Female Sexual Dysfunction characterised by a woman's inability to achieve orgasm. This condition affects 1 in 5 pre and post menopausal women worldwide. Currently there are no approved treatments for Anorgasmia and therefore the segment represents a fully unmet need for women suffering distress from this condition.

At this conference, Trimel will be presenting both Pharmaco-dynamic and Pharmaco-kinetic results obtained in a clinical trial employing its TBS 2 product. TBS 2, is a bio-identical hormone presented as a bio-adhesive intra nasal gel. The Company expects TBS 2 will be fully developed to produce a unique "taken as required" treatment for Anorgasmia. TBS 2 is currently undergoing Phase II testing in a clinical study with the established end point of demonstrating the product's ability to induce orgasm in the identified population.

About Trimel

Trimel Pharmaceuticals Corporation (TSX:TRL). Developing Medications for Female Sexual Health and Conditions related to Aging and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT, a bio-adhesive intranasal Testosterone gel for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit www.trimelpharmaceuticals.com.

Notice regarding forward-looking statements:

Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, are assumptions regarding our future operational results. These assumptions, although considered reasonable by the Company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the Company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our final prospectus which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

Contact Information

  • Trimel Pharmaceuticals Corporation
    Kenneth G. Howling
    Chief Financial Officer
    416 679 0771